镥[177Lu]氧奥曲肽肽受体放射性核素治疗多复发非间变性脑膜瘤:基于生长率分析抗肿瘤活性研究
回顾性纳入8例多复发非间变性脑膜瘤患者,评估Lutathera®治疗对三维体积生长率(3DVGR)的影响。治疗后3、6、12个月3DVGR显著下降;6个月时6/7例达2级(稳定或生长率严重减慢),6和12个月无患者达1级,提示药物反应缺失。作者认为抗肿瘤活性延迟出现且多在第6个月观察到,无主要缓解,但活性持续至治疗后12-18个月。
要点
- 8例非间变性脑膜瘤(7例WHO 2级、1例侵袭性WHO 1级)接受Lutathera®治疗,除1例外均完成4个周期。
- 治疗前平均3DVGR为29.5%/6个月,治疗后3、6、12个月分别降至16.5%、9.5%、9.5%/6个月。
- 6个月时6/7例、12个月时5/6例为2级(稳定或生长率严重减慢),6和12个月无患者为1级。
核心结论
- 在非间变性脑膜瘤中,Lutathera®的抗肿瘤活性似乎延迟出现,更可能在第6个月观察到,治疗期间未见主要缓解。
- 其抗肿瘤活性在治疗开始后持续12-18个月。
研究设计与样本
- 回顾性研究,纳入8例接受Lutathera®治疗的非间变性脑膜瘤患者。
- 使用钆增强三维T1加权磁共振序列进行体积测量,并按Graillon等描述的3DVGR分类评估肿瘤生长率。
主要发现
- 患者包括7例WHO 2级脑膜瘤和1例侵袭性WHO 1级脑膜瘤。
- 除1例外,所有患者均接受4个治疗周期。
- 分别分析每个病灶,治疗开始后3、6、12个月3DVGR显著下降。
- 治疗前平均3DVGR为29.5%/6个月、中位44.5%/6个月;治疗开始后3个月平均16.5%/6个月、中位25%/6个月;6个月后平均9.5%/6个月、中位4.5%/6个月;12个月后平均9.5%/6个月、中位10.5%/6个月。
- 治疗开始后3、6、12个月分别有4/8、6/7、5/6例患者为2级(稳定或3DVGR严重减慢);6和12个月无患者为1级,提示缺乏药物反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several retrospective studies and meta-analyses of Peptide Radionuclide Radiation Therapy in meningiomas suggest six-month progression-free survival improvement for WHO grade 1 and 2 meningiomas. In the present study, we aimed to evaluate the impact of such treatment on three-dimensional volume growth rate (3DVGR) in nonanaplastic meningiomas. METHODS: The authors performed a retrospective study including eight patients treated with Lutathera®. Millimetric 3D T1-weighted with gadolinium enhancement magnetic resonance imaging sequences were requested for volume measurement. Then, tumor growth rate was classified following a previously described 3DVGR classification (Graillon et al.). RESULTS: Patients harbored seven WHO grade 2 meningiomas and one aggressive WHO grade 1. All patients, except one, underwent four treatment cycles. 3DVGR significantly decreased at 3, 6, and 12 months after treatment initiation analyzing each lesion separately. Mean and median 3DVGR from all patients were respectively at 29.5% and 44.5%/6 months before treatment initiation, then at 16.5% and 25%/6 months at three months post-treatment initiation, 9.5% and 4.5%/6 months after 6 months, as well as 9.5% and 10.5%/6 months after 12 months. At 3, 6, and 12 months after treatment initiation, 4/8, 6/7, and 5/6 patients were class 2 (stabilization or severe 3DVGR slowdown), respectively. No patient was class 1 at 6 and 12 months, suggesting a lack of drug response. CONCLUSION: In nonanaplastic meningiomas, Lutathera®'s antitumoral activity appeared delayed and more likely observed at six months, while no major response was observed under treatment. Moreover, its antitumoral activity persisted for 12-18 months following treatment initiation.
引用
- Graillon T, Salgues B, Horowitz T, et al. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. J Neurooncol. 2024. PMID: 38451361. doi:10.1007/s11060-024-04622-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。